alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › removal

removal

4 studies tagged removal, dated 2023-02-20 to 2026-08-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal 2026-08-01
  2. Passive amyloid-β immunotherapy in Alzheimer's disease: a multicellular clearance system beyond plaque removal 2026-07-16
  3. Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease 2023-10-26

Studies

4 studies carry this tag.

Date range

2023 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • Molecular neurodegeneration 1
  • Nature aging 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    ARIA are not associated with long-term parenchymal reduction; rather, they are linked to a fluid shift from the external space to the ventricles.

  2. Passive amyloid-β immunotherapy in Alzheimer's disease: a multicellular clearance system beyond plaque removal

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Molecular neurodegeneration 2026-07-16 Treatments

    Passive immunotherapy targeting amyloid-β (Aβ) has emerged as a major therapeutic strategy for Alzheimer's disease (AD), yet its clinical benefits remain modest and are frequently accompanied by vascular adverse events such as amyloid-related imaging abnormalities (ARIA).

  3. Precision medicine analysis of heterogeneity in individual-level treatment response to amyloid beta removal in early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023-10-26 Biomarkers

    This ITR analysis provides a proof of concept for precision medicine in future AD research and drug development.

  4. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Nature aging 2023-02-20 Genetics

    Apolipoprotein E4 (APOE4) is the strongest known genetic risk factor for late-onset Alzheimer's disease (AD).

All topic tags with their study counts